CJC-1295 and ipamorelin get sold as one blend, but verifying two compounds in one vial takes more than a single purity number.
CJC-1295 and ipamorelin are two separate peptides that get sold together constantly, bundled into one vial or one kit under a combined name. That bundling is exactly what makes this category harder to verify than either compound sold alone, because a single test result covering the whole vial cannot tell you what is actually in it, or in what ratio. The combination is popular enough that many listings treat CJC-1295 and ipamorelin as if they were one product with one name, rather than two peptides that happen to be sold together. That framing makes verification easy to skip past, since a buyer comparing prices across a few sites is comparing marketing pages, not the underlying documentation. This page covers research-use sourcing only, with no dosing or usage guidance. The goal is to explain what each compound is, why they get sold as a pair, and what a listing needs to show before you can trust it, one section at a time.
CJC-1295 is a long-acting analog of growth hormone releasing hormone, or GHRH. It exists in two distinct forms. One includes a drug affinity complex, known as DAC, a modification that binds to albumin in the blood and extends the compound's activity over roughly six to eight days. The other, without DAC, is sometimes called Modified GRF 1-29 and behaves more like a standard, shorter-acting GHRH analog, closer in duration to the natural hormone it is modeled on. That difference in duration is not a minor technical footnote. A long-acting, albumin-bound version and a short-acting version are, functionally, two different research tools, and a listing that just says CJC-1295 without saying which one is giving you less information than the name implies. Neither version is an approved medicine. Research databases classify CJC-1295 as investigational, tied to a Phase 2 trial for obesity that was terminated rather than completed, which is a meaningfully different outcome from a trial that finished and simply did not lead to approval. Because CJC-1295 has been studied in humans at all, it is easy for marketing copy to lean on the existence of that trial as if it were proof of safety or benefit, when a terminated Phase 2 trial is, at best, a partial and unfinished data set.
Ipamorelin works through a completely different receptor. It is a selective ghrelin receptor agonist that promotes growth hormone release partly by damping the pituitary's own braking signal, a hormone called somatostatin. Because it acts on a separate pathway from CJC-1295 rather than doing the same job in a different way, the two compounds are not redundant with each other by design. Research on ipamorelin has also described it as more selective than older growth hormone secretagogues, since it does not meaningfully raise cortisol, prolactin, or ACTH the way some earlier compounds in that class do. That selectivity is one of the reasons it shows up in research literature more favorably than some older secretagogues, independent of any claim about outcomes in people. Like CJC-1295, ipamorelin has not reached regulatory approval. It has been through a completed Phase 2 trial for a gastrointestinal indication, and research reviews classify its human safety data as limited, a status that has not changed just because the compound is widely available through research suppliers.
CJC-1295 and ipamorelin act on two different receptor pathways in the pituitary, and research literature describes the combination, using the no-DAC version of CJC-1295, as producing a synergistic rather than simply additive effect on growth hormone and IGF-1 release. That is the scientific rationale sellers point to when marketing the two together as a blend, and it is grounded in real, published mechanism, not invented marketing language. A rationale for combining two compounds is not the same as a guarantee about what is actually in a specific vial sold under that name. The existence of a plausible mechanism for why a blend might behave a certain way says nothing about whether any individual bottle on any individual website contains the ratio, purity, or even the correct pair of compounds the label claims. That gap is exactly where verification has to do the work, and it is also exactly where a blend differs from a single compound: there are simply more places for a mismatch between label and contents to hide.
A meaningful number of blend listings just say CJC-1295 without specifying whether it is the DAC or no-DAC version, even though the two behave differently enough that the distinction matters for anyone trying to understand what they are looking at. Some listings use CJC-1295 and Modified GRF interchangeably without ever clarifying which one is actually in the vial, sometimes switching between the two names on the same page. Vague naming like this is not automatically dishonest, since the terminology genuinely is inconsistent across the research peptide market, and sellers often inherit naming conventions from whichever manufacturer they buy from rather than choosing them deliberately. But it does mean the product name alone tells you less than it should, and you need the paperwork underneath it to know what you are actually buying. If a page cannot tell you, in writing, whether its CJC-1295 includes DAC, that is worth treating as a gap in documentation rather than a stylistic choice.
A single-compound certificate of analysis needs to confirm one identity and one purity figure. A blend needs to confirm two identities, one for CJC-1295 and one for ipamorelin, plus two separate amounts, because a lab result reporting only total peptide content cannot tell you the ratio between the two compounds in the vial. A blend advertised as one part CJC-1295 to one part ipamorelin needs testing that actually shows that ratio, not just a combined purity number that could hide almost any actual mix. Our guide to reading a Janoshik-style COA covers how to interpret identity and purity results generally. For a blend specifically, check that the report lists both compounds separately rather than one combined peak or one combined percentage, and check that the DAC status of the CJC-1295 component is stated somewhere in the documentation, not just inferred from the product name. A report that only shows a single peak for a product marketed as two compounds is either testing an incomplete picture, or the vial does not actually contain what the label says, and there is no way to tell which from the report alone. It is worth asking a seller directly whether their standard COA covers both compounds by name before you buy, rather than discovering after the fact that the documentation only ever addressed one half of what you paid for.
Ask for the batch-specific COA, not a generic one pulled from the product page, and check that it names both compounds and specifies which version of CJC-1295 it covers. If a seller cannot produce that for the exact lot you would receive, treat the listing as unverified regardless of how the marketing reads, since a confident product description is not a substitute for a lab result. The same checklist that applies to any peptide supplier, covering lab testing, transparency, and reputation, applies here too, just with the added step of checking that both halves of the blend are actually documented. A supplier that handles single-compound verification well is not automatically handling blend verification the same way, since it takes more from their testing process to do it properly, and it is worth checking rather than assuming.
Peptide Supplier Guide is run by the same people behind Peptide+, a supplier listed on this site, so this is not independent coverage and we do not present it that way. Every supplier here is scored on the same criteria on our how we rank page, whatever compound or blend they sell. We do not name a single best seller for this blend or any other, and we do not attribute quotes or specific claims to any named supplier. Our full list of scored suppliers is the place to compare listed sellers against those criteria yourself, using the verification steps above as the starting checklist for any blend listing specifically.
Research-use information only. Not medical advice.